



FOR IMMEDIATE RELEASE

Contact: Holly P. Glass  
[holly.glass@semprusbio.com](mailto:holly.glass@semprusbio.com)  
703.754.2848

## **SEMPRUS BIOSCIENCES APPOINTS TWO NEW EXECUTIVES**

*Donald G. Anderson; Vice President, Business Development &  
Laurence A. Roth; Vice President, Product Development*

**Cambridge, MA** (February 15, 2010)—[Semprus BioSciences](http://www.semprusbio.com), Corp., today announced the appointment of Donald G. Anderson to the position of Vice President, Business Development, and Laurence A. Roth to the position of Vice President, Product Development; both appointments are effective immediately.

Prior to accepting his appointment, Anderson was managing director of Boston-based Cavan Partners, LLC – a life science consulting firm he co-founded in 2002. There, he served as a consultant to Semprus BioSciences since 2008. From 2000-2002, he was vice president of marketing and business development for Biosphere Medical, Inc. Anderson co-founded two medical device start-up companies; he worked collaboratively to take one company through the IPO process, and another through an acquisition by Edwards Lifesciences. He has held senior executive positions in sales and marketing from 1979-95 with Wyeth, Inc., and a vascular access division of Pfizer, Inc.

Anderson holds a BA in economics from Dartmouth College and a MBA with high honors from Babson College. He has also completed the Executive Management Program at the Columbia School of Business.

Before joining [Semprus Biosciences](http://www.semprusbio.com), Roth served as an independent medical device industry consultant, providing product development and business strategy services to development stage companies. Before starting his consulting business, Roth held executive roles in product development, business development and operations for three venture-backed device companies in the Boston area – Arsenal Medical, Inc., Percardia, and Focal, Inc. (acquired by Genzyme, Inc.) – since 1992. He began his career at C. R. Bard, Inc., where he held a variety of engineering and project management positions over 13 years.

Roth earned a BS and a ME in Biomedical Engineering from Rensselaer Polytechnic Institute and a MBA from Babson College.

“Don and Larry are widely recognized for their impressive, proven track records in the medical device industry and will be valuable additions to our expanding management team,” said [Semprus Biosciences](http://www.semprusbio.com) Chief Executive Officer and co-founder, David L. Lucchino. “Their vast business and product development experience are an ideal fit with Semprus BioSciences as we deliver our proprietary ‘super biomaterial’, [Semprus Surface](http://www.semprusbio.com)™, to the vascular access market – and beyond,” he added.

###

*Semprus BioSciences, headquartered in Cambridge, Massachusetts, spun out of the famed labs of MIT researcher, Dr. Robert Langer, and raised \$8 million in Series A financing in December 2008. The company has a dual mission: to provide complication-free medical devices designed to preserve patients’ long-term health and quality-of-life, and to contribute to health care cost efficiencies. Our innovative, multi-faceted Semprus Surface™ product signifies a breakthrough in medical device technology. It provides an “anti-biofilm and anti-thrombogenic” solution that can deliver the first permanently dual-functional vascular access catheter with a single surface modification. This multi-dimensional Semprus Surface™ is also designed with the capabilities of effectively delivering drugs from or immobilizing agent on the Semprus Surface™ to address a wide range of clinical problems. Visit [www.semprusbio.com](http://www.semprusbio.com) for additional information.*